This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069–80.
Stevenson ML, Wang CQ, Abikhair M, et al. Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab. JAMA Dermatol 2017; 153: 299–303.
Cohen EEW, Soulières D, LeTourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019; 393: 156–67.
Eggermont AMM, Blank CU, Mandala M, et al. adjuvant pembrolizumab versus placebo in resected Stage III melanoma. N Engl J Med 2018; 378: 1789–801.
Lee CH, Yelensky R, Jooss K, Chan TA. Update on tumor neoantigens and their utility: why it is good to be different. Trends Immunol 2018; 39: 536–48.
Garcia-Diez I, Hernandez-Ruiz E, Andrades E, et al. PD-L1 Expression is increased in metastasizing squamous cell carcinomas and their metastases. Am J Dermatopathol 2018; 40: 647–54.
Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: The Australian experience. Cancer 1999; 85: 1758–64.
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681–91.
Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81: 1093–100.
Saavedra D, García B. Immunosenescence: effects of aging process on immune system. Rev Cubana Hematol Inmunol Hemoter 2014; 30: 332–45.
Financial support: none. Conflicts of interest: none.
About this article
Cite this article
Mora-Fernández, V., Boada, A., Manzano, JL. et al. Locally advanced head and neck squamous cell carcinoma and melanoma simultaneously treated with pembrolizumab: an unusual situation. Eur J Dermatol 30, 743–744 (2020). https://doi.org/10.1684/ejd.2020.3911